<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92512">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032654</url>
  </required_header>
  <id_info>
    <org_study_id>NL44512.018.13</org_study_id>
    <nct_id>NCT02032654</nct_id>
  </id_info>
  <brief_title>Duration of ANtibiotic Therapy for CEllulitis</brief_title>
  <acronym>DANCE</acronym>
  <official_title>Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cellulitis is among the most common infections leading to hospitalization, yet the optimal
      duration of therapy remains ill defined. Pragmatically, Dutch guidelines advise 10-14 days
      of antibiotics, which is the current standard of care. Recently it has been shown that
      antibiotic treatment for pneumonia and urinary tract infections can safely and significantly
      be shortened. Importantly, in an outpatient setting, treatment of uncomplicated cellulitis
      with 5 days of antibiotics was as effective as 10 days. We hypothesize that there is no
      difference in outcomes when patients hospitalized with cellulitis are treated with either a
      short-course (6 days) or standard-course (12 days) of antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part 1/2: Resolution...</measure>
    <time_frame>day 14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Resolution of cellulitis at day 14, defined as disappearance of warmth and tenderness at the site of infection, with substantial improvement in erythema and edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2/2: ...without relapse</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>No recurrence by day 28, defined as the need for additional antibiotic therapy for cellulitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence at day 90</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recurrence of cellulitis by day 90, defined as the need for additional antibiotic therapy for cellulitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective speed of recovery</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in cellulitis severity score (a 7 item scoring system, each with a score between 0-3; items are erythema, warmth, tenderness, edema, ulceration, drainage and fluctuance). Determined at day 1, day 2-3, day 5-6, day 14, and day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using questionnaires Dutch SF-36 and EQ-5D at day 1, day 28, and day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource utilisation</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determined by total antibiotic use and effect on direct and indirect health-care associated costs, using modified versions of iMTA's Productivity Cost Questionnaire (iPCQ) and Medical Consumption Questionnaire (iMCQ). Measured at day 5-6, day 28 and day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective speed of recovery</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analog Scales (0-10) on pain and on swelling. Determined at day 1, day 2-3, day 5-6, day 14, day 28, and day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional antibiotic usage</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total usage of additional antibiotics for cellulitis between the end of treatment and day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time between end of treatment and the need for additional antibiotics for cellulitis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellulitis severity score subgroup analysis</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis to see if the height of the cellulitis severity score influences outcome, using a regression analysis with interaction term for severity score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes mellitus subgroup analysis</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis to see if having diabetes mellitus influences outcome, using a regression analysis with interaction term for diabetes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Per protocol analysis</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Like main outcome, but the following will be included: (i) patients with treatment failure, who have received at least 24 hours of study medication, and (ii) patients with treatment success, who have received at least 80% of study medication. Treatment failure is defined as the persistence or progression of signs and symptoms of the acute process after randomization, or the inability to complete the study owing to adverse events. The response is deemed indeterminate when the patients (i) received less than 80% of the study drug for reasons other than treatment failure, (ii) acquired a concomitant infection outside of the skin requiring antibiotic treatment, (iii) were lost to follow-up, or (iv) died unrelated to the primary diagnosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjustments for baseline covariates</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity analysis, adjusting the primary outcome for baseline covariates</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Cellulitis</condition>
  <condition>Erysipelas</condition>
  <arm_group>
    <arm_group_label>Standard course</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short course</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucloxacillin</intervention_name>
    <arm_group_label>Standard course</arm_group_label>
    <arm_group_label>Short course</arm_group_label>
    <other_name>Floxapen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for flucloxacillin)</intervention_name>
    <description>Sugar capsule manufactured to mimic flucloxacillin 500mg capsules</description>
    <arm_group_label>Short course</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to receive intravenous antibiotics for cellulitis/erysipelas

          -  18 years of age or older

          -  Capable of giving written informed consent, able to comply with study requirements
             and restrictions

        Exclusion Criteria:

          -  Allergy for flucloxacillin, other beta-lactam antibiotics or one of the additives, or
             flucloxacillin induced hepatitis or liver enzyme disorders.

          -  Concurrent use of antibiotics for other indications

          -  Alternative diagnosis accounting for the clinical presentation.

          -  All cases involving any of the following complicating factors:

               -  Use of antibiotics with Gram-positive activity for more than 4 days in the past
                  7 days

               -  Intensive care unit admission during the last 7 days

               -  Severe peripheral arterial disease (Fontaine IV)

               -  Severe cellulitis necessitating surgical debridement or fascial biopsy

               -  Necrotizing fasciitis

               -  Periorbital or perirectal involvement

               -  Surgery

               -  Life expectancy less than one month

               -  Risk factors associated with Gram-negative pathogens as a causative agent:

                    -  Chronic or macerated infra-malleolar ulcers, or infra-malleolar ulcers with
                       previous antibiotic treatment, in patients with diabetes mellitus.

                    -  Neutropenia

                    -  Cirrhosis (Child-Pugh class B or C)

                    -  Intravenous drug use

                    -  Human or animal bite

                    -  Skin laceration acquired in fresh or salt open water

                    -  Fish fin or bone injuries
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Joost Wiersinga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center - University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan M. Prins, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center - University of Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duncan R. Cranendonk, MD</last_name>
    <phone>+31205665247</phone>
    <email>d.r.cranendonk@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>W. Joost Wiersinga, MD, PhD</last_name>
    <phone>+31205661109</phone>
    <email>w.j.wiersinga@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <state>Flevoland</state>
        <zip>1300EG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J. Branger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center - University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duncan R. Cranendonk, MD</last_name>
      <phone>+31205665247</phone>
      <email>d.r.cranendonk@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Duncan R. Cranendonk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>W. Joost Wiersinga, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan M. Prins, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU university medical center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M. A. van Agtmael, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1087CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>K. Brinkman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J. Veenstra, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slotervaartziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>F. N. Lauw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>I. M. Hoepelman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <zip>3582KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>S. U. C. Sankatsing, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dancetrial.nl</url>
    <description>Trial website, in Dutch</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>W.J. Wiersinga, MD, PhD</investigator_full_name>
    <investigator_title>internist, infectious diseases specialist</investigator_title>
  </responsible_party>
  <keyword>antibiotics</keyword>
  <keyword>flucloxacillin</keyword>
  <keyword>therapy duration</keyword>
  <keyword>cellulitis</keyword>
  <keyword>erysipelas</keyword>
  <keyword>skin infections</keyword>
  <keyword>hospital</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Erysipelas</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
